MetaVia Eulerpool News

MetaVia Stock News

MetaVia is being monitored by journalists and investors worldwide. We gather the latest MetaVia news here.

• February 13 ·

  Benzinga
  MetaVia Announces Global IP Portfolio Supporting DA-1726, Dual OXM Analog Agonist That Functions As GLP1R And GCGR, For Treatment Of Obesity And Related Metabolic Disorders
• February 4 ·

  Yahoo
  MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel
• January 21 ·

  Yahoo
  MTVA: Positive Results for 48 mg Cohort in Phase 1b Trial of DA-1726…
• January 21 ·

  Benzinga
  Watching MetaVia; Zacks Small-Cap Research Gives Stock $60 Price Valuation
• January 15 ·

  Yahoo
  MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering
• December 29 ·

  Yahoo
  MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference
• November 10 ·

  Yahoo
  MTVA: 8-Week Data for 48 mg Cohort in Phase 1 Obesity Study Expected Before End of 2025…
• September 16 ·

  Benzinga
  Why Webtoon Entertainment Shares Are Trading Higher By 48%; Here Are 20 Stocks Moving Premarket
• August 4 ·

  Benzinga
  Metavia Announces A Research Collaboration With Syntekabio To Identify Additional Disease Targets And Optimize The Therapeutic Profile Of DA-1241, Metavia's Novel Oral G-Protein-Coupled Receptor 119 Agonist
• June 24 ·

  Yahoo
  MTVA: DA-1241 in Combination with Efruxifermin Shows Additive Hepatoprotective Effects in Mouse MASH Model…
• June 21 ·

  Yahoo
  MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session
• June 13 ·

  Yahoo
  Life Sciences Investor Forum: Now Available for Online Viewing
• June 10 ·

  Yahoo
  MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th
• June 4 ·

  Yahoo
  MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions
• May 22 ·

  Yahoo
  MTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study…
• May 14 ·

  Yahoo
  MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update
• May 7 ·

  Yahoo
  MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025
• April 16 ·

  Yahoo
  MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…
• April 15 ·

  Benzinga
  MetaVia's Top-Line Data From 4-Week Phase 1 MAD Trial of DA-1726 Shows Compelling Weight Loss and Safety Effects With Potential GLP-1R, Waist Reduction and Tolerability
• March 31 ·

  Yahoo
  MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon…

MetaVia Stock Press Releases

MetaVia regularly publishes news on the company's website that are relevant for investors.